Efficacy and safety of canakinumab in patients with Adult-Onset Still's Disease: Results from an open-label Phase III study in Japan
{{output}}
Objectives: To evaluate the efficacy and safety of canakinumab 4 mg/kg every 4 weeks administered subcutaneously in Japanese AOSD patients. Methods: ... ...
